ReviewFrontiers in nuclear medicine2025
Population pharmacokinetic modeling in radiopharmaceutical therapy: a review.
Review in Frontiers in nuclear medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Preliminary feasibility of pre-treatment F-18-PSMA-1007 PET/CT in dose prediction for Lu-177-PSMA-I&T therapy.Acta oncologica (Stockholm, Sweden) · 2026Article
- Cellular Heterogeneity in Drug Uptake Amplifies Pharmacodynamic Variability: A Stochastic PK-PD Analysis.CPT: pharmacometrics & systems pharmacology · 2026Article
- Towards practical radiopharmaceutical treatment planning: a review of dosimetry simplification techniques.Theranostics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Population pharmacokinetic (PopPK) has emerged as a robust framework for characterizing inter-individual variability in the absorbed dose estimates in radiopharmaceutical therapy (RPT). By enabling the analysis of biokinetic data from heterogeneous patient populations, PopPK allows individualized absorbed dose estimates while simultaneously leveraging population-level information. This review presents and evaluates the current applications of PopPK, such as nonlinear mixed-effects modeling (NLMEM) and Bayesian fitting methods in RPT, emphasizing its advantages over traditional individual-based modeling approaches. We summarize key studies that have implemented PopPK for modeling radiopharmaceutical biokinetics, with a focus on time-integrated activity (TIA) estimation, including single-time-point (STP) dosimetry, uncertainty analysis, as well as pharmacodynamic (PD) analysis. The flexibility of PopPK in handling sparse and irregularly sampled data makes it particularly relevant for clinical scenarios where comprehensive imaging schedules are impractical. However, despite its potential, the widespread adoption of PopPK in RPT remains limited due to challenges such as computational complexity and the need for specialized expertise. This review discusses critical aspects of PopPK implementation while emphasizing the importance of interdisciplinary collaboration in translating PopPK methodologies into clinical practice. Future directions include integrating PopPK into adaptive dosimetry frameworks and applying it in STP dosimetry and PD modeling to optimize treatment personalization. By providing a comprehensive overview of PopPK applications in RPT, this review aims to facilitate the integration of advanced modeling techniques into routine clinical workflows, ultimately supporting the development of accurate and precise RPTs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.